DOK1 mediates SHP-2 binding to the αVβ3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells

被引:42
作者
Ling, Y [1 ]
Maile, LA [1 ]
Badley-Clarke, J [1 ]
Clemmons, DR [1 ]
机构
[1] Univ N Carolina, Div Endocrinol, Sch Med, Chapel Hill, NC 27599 USA
关键词
D O I
10.1074/jbc.M411035200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recruitment of the Src homology 2 domain tyrosine phosphatase (SHP-2) to the phosphorylated beta3 subunit of the alphaVbeta3 integrin is required for insulin-like growth factor I (IGF-I)-stimulated cell migration and proliferation in vascular smooth muscle cells. Because SHP-2 does not bind directly to 133, we attempted to identify a linker protein that could mediate SHP-2/beta3 association. DOK1 is a member of insulin receptor substrate protein family that binds 133 and contains YXXL/I motifs that are potential binding sites for SHP-2. Our results show that IGF-I induces DOK1 binding to beta3 and to SHP-2. Preincubation of cells with synthetic peptides that blocked either DOK1/beta3 or DOK1/SHP-2 association inhibited SHP-2 recruitment to beta3. Expression of a DOK1 mutant that does not bind to 133 also disrupts SHP-2/beta3 association. As a result of SHP-2/beta3 disruption, IGF-I dependent phosphorylation of Akt and p44/p42 mitogen-activated protein kinase and its ability to stimulate cell migration and proliferation were significantly impaired. These results demonstrate that DOK1 mediates SHP-2/beta3 association in response to IGF-I thereby mediating the effect of integrin ligand occupancy on IGF-IR-linked signaling in smooth muscle cells.
引用
收藏
页码:3151 / 3158
页数:8
相关论文
共 30 条
[1]   Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains:: A structural prototype for diversity in integrin signaling [J].
Calderwood, DA ;
Fujioka, Y ;
de Pereda, JM ;
García-Alvarez, B ;
Nakamoto, T ;
Margolis, B ;
McGlade, CJ ;
Liddington, RC ;
Ginsberg, MH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2272-2277
[2]  
CASE RD, 1994, J BIOL CHEM, V269, P10467
[3]  
ELLIS C, 1991, ONCOGENE, V6, P895
[4]  
Goel HL, 2004, J CELL BIOL, V166, P407, DOI 10.1083/jcb.200403003
[5]   VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR PROMOTES TYROSINE PHOSPHORYLATION OF MEDIATORS OF SIGNAL-TRANSDUCTION THAT CONTAIN SH2 DOMAINS - ASSOCIATION WITH ENDOTHELIAL-CELL PROLIFERATION [J].
GUO, DQ ;
JIA, Q ;
SONG, HY ;
WARREN, RS ;
DONNER, DB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (12) :6729-6733
[6]  
Ho A, 2001, CANCER RES, V61, P474
[7]   Inhibition of the motility and growth of B16F10 mouse melanoma cells by dominant negative mutants of Dok-1 [J].
Hosooka, T ;
Noguchi, T ;
Nagai, H ;
Horikawa, T ;
Matozaki, T ;
Ichihashi, M ;
Kasuga, M .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (16) :5437-5446
[8]   Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyriboncleic acid synthesis by insulin-like growth factor-I [J].
Imai, Y ;
Clemmons, DR .
ENDOCRINOLOGY, 1999, 140 (09) :4228-4235
[9]   Ligand occupancy of the alpha V beta 3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor I [J].
Jones, JI ;
Prevette, T ;
Gockerman, A ;
Clemmons, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2482-2487
[10]   Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia [J].
Lee, S ;
Roy, F ;
Galmarini, CM ;
Accardi, R ;
Michelon, J ;
Viller, A ;
Cros, E ;
Dumontet, C ;
Sylla, BS .
ONCOGENE, 2004, 23 (13) :2287-2297